Developing the world’s 1st scalable, end-to-end system for cost-efficient, sustainable cultivated pork meat production

全球粮食系统需要增加50%的粮食产量，以维持未来40年不断增长的人口，同时大幅减少温室气体(GHG)排放(社会市场基金会，2020年)。总排放量的14%归因于畜牧业。在整个价值链不发生变化的情况下，到2050年，这些排放可能会增加30-40%(IPCC，2020)。养殖肉类(CM)可以成为动物养殖的一种安全和可持续的替代方案。猪肉是最广泛消费的肉类(联合国粮农组织，2020年)。据估计，种植猪肉的温室气体排放量为-75%，土地需求为-72%(Good Food Institute，2021年)。虽然目前的生产成本比动物养殖产品高出100-10,000倍，但如果有合适的放大技术，价格可能在2030年前达到一个竞争点。该行业的发展一直很缓慢，但在过去的十年里，CM已经从2013年的第一个汉堡成本25万美元，到2023年在美国获得批准并在新加坡销售的培育鸡。动物替代技术(AAT)是一家位于剑桥大学的B2B公司。我们正在为CM生产创建一个可扩展的端到端系统，包括专业的生物工艺、使能技术和软件。我们的使命是使获得可持续食品的途径民主化，并应对世界上最大的可持续性和粮食安全挑战。在这个研发项目中，我们与Cellivate的合作旨在开发世界上第一个端到端、低成本高效的培育猪肉生产系统，使肉类生产商能够大规模商业化生产自己定制的培育猪肉产品，这些产品营养丰富、美味可供一般消费、对环境的影响更低、质量更高、更强大的本地供应链和道德来源。我们将通过将我们的非转基因细胞系与Cellivate专有的10倍廉价的不含动物成分的培养基和定制的可食用支架在我们新颖的、可扩展的专门建造的生物反应器中进行优化和组合，然后扩大规模。到目前为止，我们已经从风投和战略投资者那里筹集了300万GB，并开发了几项专利/开创性技术，包括细胞系和生物电子传感器。我们的工作获得了多个奖项，AAT参与了4个加速器。我们曾在TechCrunch、Food Navigator、The Spoon等网站上亮相，并专注于食品安全和可持续性。Cellivate开发了专利纳米技术，使细胞能够更好、更快地生长。他们的产品组合包括可食用支架、生物材料和无血清介质，这些都加速了CM的发展。Cellivate入选了Good Food Institute的“2020亚洲百人组”榜单。它获得了三井化学、ASPIRE实验室的奖励/认可，并在多个出版物和播客中进行了专题报道。

Global food systems need to produce 50% more food to sustain growing populations over the next 40 years, whilst substantially reducing greenhouse gas (GHG) emissions (Social Market Foundation,2020). 14% of total emissions are attributable to animal farming. Without changes throughout the value chain, these emissions are likely to increase by 30-40% by 2050(IPCC,2020).Cultivated meat (CM) can be a safe and sustainable alternative to animal farming. Pork is the most widely consumed meat(UN-FAO,2020). Cultivated pork is estimated to have -75% GHG emissions and -72% land requirements(Good Food Institute,2021). While production costs are currently 100-10,000x higher than for animal-farmed products, with the right scale-up technologies, prices could reach a competitive point before 2030\. Progress in the industry has been slow, but in the last decade, CM has gone from its 1st burger costing \>$250,000 in 2013 to cultivated chicken being approved in the USA and sold in Singapore by 2023\.Animal Alternative Technologies(AAT) is a B2B company located at the University of Cambridge. We are creating a scalable, end-to-end system for CM production, including specialist bioprocesses, enabling technologies, and software. Our mission is to democratise access to sustainable food and tackle the world's biggest sustainability and food security challenges. Our collaboration with Cellivate during this R&D project aims to develop the world's 1st end-to-end, cost-efficient cultivated pork production system that enables meat producers to commercially manufacture at large scales their own tailored, cultivated pork products, which are nutritious, delicious for general consumption, with lower environmental impact, higher quality, stronger local supply chains, and ethical sources. We will do this by optimizing and combining our non-GMO cell lines with Cellivate's proprietary 10x cheaper animal-component-free media and customized edible scaffolds in our novel, scalable purpose-built bioreactors, and then scaling up.To date, we have raised \>£3 million from VCs and strategic investors, and have developed several patents/pioneering technologies, including cell lines and bioelectronic sensors. Our work has received multiple awards, and AAT has participated in 4 accelerators. We have been featured in TechCrunch, Food Navigator, The Spoon, etc., and are focused on food security and sustainability. Cellivate has developed patented nanotech technologies that enable cells to grow better and faster. Their portfolio includes edible scaffolds, biomaterials and serum-free media, which accelerate CM development. Cellivate was in the Good Food Institute's "2020 Asia Alt 100" list. It has received awards/recognition from Mitsui Chemicals, ASPIRE Labs and has been featured in multiple publications and podcasts.